All In Biotech

NDA 217785 · Madrigal

Rezdiffra

Resmetirom · Oral · Thyroid Hormone Receptor beta Agonist

NovelBreakthrough therapyAccelerated approvalPriority review

CDER novel approval, Mar 14, 2024: To treat noncirrhotic non-alcoholic steatohepatitis with moderate to advanced liver scarring

Last checked: Nov 20, 2026Latest source record: Jul 24, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Mar 14, 2024

Approved uses

1

Original approval plus efficacy supplements

Registered trials

23

4 Phase 3, 7 recruiting

FAERS reports

2,298

834 serious, 125 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 29, 2026.

REZDIFFRA ® is indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis). This indication is approved under accelerated approval based on improvement of MASH and fibrosis [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. Limitations of Use Avoid use of REZDIFFRA in patients with decompensated cirrhosis [see Use in Specific Populations (8.7) , Clinical Pharmacology (12.3) ] . REZDIFFRA ® is a thyroid hormone receptor-beta (THR-beta) agonist indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis). This indication is approved under accelerated approval based on improvement of MASH and fibrosis. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. (1) Limitations of Use Avoid use of REZDIFFRA in patients with decompensated cirrhosis. (1)

Therapeutic areas: Infectious disease and vaccines · Gastroenterology and liver · Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 14, 2024 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalLabelLetterReview
3 products under this application
  • REZDIFFRA · RESMETIROM 60MG · TABLET, ORAL · Prescription
  • REZDIFFRA · RESMETIROM 80MG · TABLET, ORAL · Prescription
  • REZDIFFRA · RESMETIROM 100MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Resmetirom" as an intervention, any sponsor and status, largest first.

All 23 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea368
  • nausea320
  • pruritus301
  • hepatic cirrhosis175
  • fatigue169
  • alanine aminotransferase increased161
  • aspartate aminotransferase increased149
  • abdominal pain upper138
  • weight decreased131
  • dizziness125
  • vomiting117
  • abdominal pain103

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20201
20211
20221
2024285
2025929
20261,081

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Rezdiffra (Resmetirom)

2024 spending

$69.1M

Beneficiaries

4,626

14,964 claims

Per beneficiary

$14,939

$131.97 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$69,106,677

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 32 on PubMed

Sponsor: Madrigal

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.